Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: July 17, 2018

DrugPatentWatch Database Preview

Jubilant Generics Company Profile

« Back to Dashboard

What is the competitive landscape for JUBILANT GENERICS, and what generic and branded alternatives to JUBILANT GENERICS drugs are available?

JUBILANT GENERICS has thirty-nine approved drugs.

Summary for Jubilant Generics

US Patents:	0
Tradenames:	35
Ingredients:	34
NDAs:	39
Patent Litigation for Jubilant Generics:	See patent lawsuits for Jubilant Generics

Drugs and US Patents for Jubilant Generics

+ Get email alerts for changes to this table

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Jubilant Generics	AMLODIPINE AND OLMESARTAN MEDOXOMIL	amlodipine besylate; olmesartan medoxomil	TABLET;ORAL	207450-001	May 15, 2017	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Jubilant Generics	CELECOXIB	celecoxib	CAPSULE;ORAL	207061-001	Apr 4, 2017	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Jubilant Generics	FELODIPINE	felodipine	TABLET, EXTENDED RELEASE;ORAL	203983-002	Aug 19, 2016	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Jubilant Generics	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	205528-002	Nov 27, 2015	AB	RX	No	No		➤ Sign Up				➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice

Mallinckrodt

Federal Trade Commission

Fish and Richardson

Express Scripts

QuintilesIMS

Cipla

Baxter

AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.